The goal of this proposal is to construct a vaccine that is broadly protective against multiple enteropathogens of public health importance to the U.S. population. These include Shigella, enterotoxigenic E. coli (ETEC) and the emerging pathogens Shiga toxin producing E. coli (STEC and enteroaggregative E. coli (EAEC). Such a multivalent vaccine would also provide protection against emerging pathogens that have acquired new virulence factors such as the Shiga toxin-expressing EAEC German outbreak strain. These enteropathogens are all Category B risk agents of biodefense concern. A vaccine with broad coverage against this group would be beneficial to multiple segments of the US population, including: 1) adult and child travelers who visit less developed countries where these infections are hyperendemic;2) children in certain high risk areas of the US;3) and for mass immunization in the face a natural or deliberate outbreak scenario. Immunization by the mucosal route is an effective method for induction of mucosal and systemic immune responses, believed to be important in protection against these enteropathogens. Our successful completion of 5 attenuated Shigella live vector strains during the Mid- Atlantic RCE (MARCE) funding period, provides the platform for the expression of protective antigens from each enteropathogen. Chromosomal insertion technology and autotransporter-based surface expression of heterologous antigens will ensure stability of vaccine constructs and optimal presentation to the host. In order to confirm the safety, immunogenicity and protective capacity of the multivalent vaccine, we have recruited expert collaborators who have developed innovative, relevant animal models for each component enteropathogen. These studies will constitute preclinical evaluations necessary for advancement to clinical trials. The multivalent vaccine will be tested in the neonatal mouse model in order to assess its utility in the very young thus expanding the potential target population age range. At the completion of these studies, we expect to have completed the construction and testing of a multivalent vaccine consisting of a mixture of live attenuated Shigella strains expressing critical antigens from ETEC, STEC and EAEC that will be broadly protective against enteric infections with these pathogens. The genetic related of these pathogens makes them well suited for grouping in this vaccine strategy that represents an important part of the overall program to develop an Immunoprophylactic Strategy to Control Emerging Enteric Infections.

Public Health Relevance

A vaccine will be developed that is broadly protective against multiple enteropathogens of public health importance to US and global populations including Shigella, STEC, EAEC and ETEC. This multivalent vaccine could also protect against infections with emerging bacterial pathogens which are acquired additional virulence factors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109776-01
Application #
8652660
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$955,045
Indirect Cost
$236,809
Name
University of Maryland Baltimore
Department
Type
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Su, Yi-Hsuan; Warren, Cirle A; Guerrant, Richard L et al. (2014) Dielectrophoretic monitoring and interstrain separation of intact Clostridium difficile based on their S(Surface)-layers. Anal Chem 86:10855-63
Huang, Tuxiong; Li, Shan; Li, Guangchao et al. (2014) Utility of Clostridium difficile toxin B for inducing anti-tumor immunity. PLoS One 9:e110826